These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38447463)

  • 1. Design, synthesis, biological evaluation and docking study of some new aryl and heteroaryl thiomannosides as FimH antagonists.
    Mohammed AF; Othman SA; Abou-Ghadir OF; Kotb AA; Mostafa YA; El-Mokhtar MA; Abdu-Allah HHM
    Bioorg Chem; 2024 Apr; 145():107258. PubMed ID: 38447463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.
    Mydock-McGrane LK; Cusumano ZT; Janetka JW
    Expert Opin Ther Pat; 2016; 26(2):175-97. PubMed ID: 26651364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of thiomannosides, potent and orally active FimH inhibitors.
    Sattigeri JA; Garg M; Bhateja P; Soni A; Rauf ARA; Gupta M; Deshmukh MS; Jain T; Alekar N; Barman TK; Jha P; Chaira T; Bambal RB; Upadhyay DJ; Nishi T
    Bioorg Med Chem Lett; 2018 Sep; 28(17):2993-2997. PubMed ID: 30017316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI.
    Jarvis C; Han Z; Kalas V; Klein R; Pinkner JS; Ford B; Binkley J; Cusumano CK; Cusumano Z; Mydock-McGrane L; Hultgren SJ; Janetka JW
    ChemMedChem; 2016 Feb; 11(4):367-73. PubMed ID: 26812660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intervening with urinary tract infections using anti-adhesives based on the crystal structure of the FimH-oligomannose-3 complex.
    Wellens A; Garofalo C; Nguyen H; Van Gerven N; Slättegård R; Hernalsteens JP; Wyns L; Oscarson S; De Greve H; Hultgren S; Bouckaert J
    PLoS One; 2008 Apr; 3(4):e2040. PubMed ID: 18446213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insightful Improvement in the Design of Potent Uropathogenic
    Mousavifar L; Sarshar M; Bridot C; Scribano D; Ambrosi C; Palamara AT; Vergoten G; Roubinet B; Landemarre L; Bouckaert J; Roy R
    Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of mannosyl triazoles as FimH antagonists.
    Schwardt O; Rabbani S; Hartmann M; Abgottspon D; Wittwer M; Kleeb S; Zalewski A; Smieško M; Cutting B; Ernst B
    Bioorg Med Chem; 2011 Nov; 19(21):6454-73. PubMed ID: 21962988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an aggregation assay to screen FimH antagonists.
    Abgottspon D; Rölli G; Hosch L; Steinhuber A; Jiang X; Schwardt O; Cutting B; Smiesko M; Jenal U; Ernst B; Trampuz A
    J Microbiol Methods; 2010 Sep; 82(3):249-55. PubMed ID: 20620174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin.
    Bouckaert J; Berglund J; Schembri M; De Genst E; Cools L; Wuhrer M; Hung CS; Pinkner J; Slättegård R; Zavialov A; Choudhury D; Langermann S; Hultgren SJ; Wyns L; Klemm P; Oscarson S; Knight SD; De Greve H
    Mol Microbiol; 2005 Jan; 55(2):441-55. PubMed ID: 15659162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tyrosine gate as a potential entropic lever in the receptor-binding site of the bacterial adhesin FimH.
    Wellens A; Lahmann M; Touaibia M; Vaucher J; Oscarson S; Roy R; Remaut H; Bouckaert J
    Biochemistry; 2012 Jun; 51(24):4790-9. PubMed ID: 22657089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease.
    Mydock-McGrane LK; Hannan TJ; Janetka JW
    Expert Opin Drug Discov; 2017 Jul; 12(7):711-731. PubMed ID: 28506090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FimH antagonists: structure-activity and structure-property relationships for biphenyl α-D-mannopyranosides.
    Pang L; Kleeb S; Lemme K; Rabbani S; Scharenberg M; Zalewski A; Schädler F; Schwardt O; Ernst B
    ChemMedChem; 2012 Aug; 7(8):1404-22. PubMed ID: 22644941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetic properties of carbohydrate-lectin interactions: FimH antagonists.
    Scharenberg M; Jiang X; Pang L; Navarra G; Rabbani S; Binder F; Schwardt O; Ernst B
    ChemMedChem; 2014 Jan; 9(1):78-83. PubMed ID: 24357503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based drug design and optimization of mannoside bacterial FimH antagonists.
    Han Z; Pinkner JS; Ford B; Obermann R; Nolan W; Wildman SA; Hobbs D; Ellenberger T; Cusumano CK; Hultgren SJ; Janetka JW
    J Med Chem; 2010 Jun; 53(12):4779-92. PubMed ID: 20507142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interdomain interaction in the FimH adhesin of Escherichia coli regulates the affinity to mannose.
    Aprikian P; Tchesnokova V; Kidd B; Yakovenko O; Yarov-Yarovoy V; Trinchina E; Vogel V; Thomas W; Sokurenko E
    J Biol Chem; 2007 Aug; 282(32):23437-46. PubMed ID: 17567583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sites for Dynamic Protein-Carbohydrate Interactions of O- and C-Linked Mannosides on the E. coli FimH Adhesin.
    Touaibia M; Krammer EM; Shiao TC; Yamakawa N; Wang Q; Glinschert A; Papadopoulos A; Mousavifar L; Maes E; Oscarson S; Vergoten G; Lensink MF; Roy R; Bouckaert J
    Molecules; 2017 Jul; 22(7):. PubMed ID: 28671638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Heptylmannoside-Based Glycoconjugate Antiadhesive Compounds against Adherent-Invasive Escherichia coli Bacteria Associated with Crohn's Disease.
    Sivignon A; Yan X; Alvarez Dorta D; Bonnet R; Bouckaert J; Fleury E; Bernard J; Gouin SG; Darfeuille-Michaud A; Barnich N
    mBio; 2015 Nov; 6(6):e01298-15. PubMed ID: 26578673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Conformational Variability of FimH: Which Conformation Represents the Therapeutic Target?
    Eris D; Preston RC; Scharenberg M; Hulliger F; Abgottspon D; Pang L; Jiang X; Schwardt O; Ernst B
    Chembiochem; 2016 Jun; 17(11):1012-20. PubMed ID: 26991759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RMSD analysis of structures of the bacterial protein FimH identifies five conformations of its lectin domain.
    Magala P; Klevit RE; Thomas WE; Sokurenko EV; Stenkamp RE
    Proteins; 2020 Apr; 88(4):593-603. PubMed ID: 31622514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation of Tyr137 of the universal
    Rabbani S; Krammer EM; Roos G; Zalewski A; Preston R; Eid S; Zihlmann P; Prévost M; Lensink MF; Thompson A; Ernst B; Bouckaert J
    IUCrJ; 2017 Jan; 4(Pt 1):7-23. PubMed ID: 28250938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.